Oxford Biomedica Reports Robust H1 Growth, Reaffirms FY 2025 Outlook

Oxford Biomedica isn’t just growing; it’s scaling with surgical precision. Today’s H1 trading update reveals a CDMO firing on all cylinders, executing its strategy with impressive momentum and reinforcing its position as a critical partner in the high-stakes world of cell and gene therapy.

Robust Growth & Rock-Solid Guidance

The headline numbers are undeniably strong:

• H1 2025 Revenue: Expected £70-73 million. That’s a hefty 38-44% leap compared to H1 2024 (£51m).
• Commercial Surge: The real stunner? £149 million in new client orders signed during H1 2025. This absolutely dwarfs the £56m secured in H1 2024 – more than double.
• FY 2025 Confidence: Full-year guidance is firmly reiterated: £160-170 million revenue (constant currency) and low single-digit Operating EBITDA profitability. Crucially, over £165 million of that 2025 revenue is already contracted – significantly up from £103m contracted this time last year.
• Revenue Backlog: Sitting pretty at a healthy £222 million as of 30 June 2025 (up from £150m at end-Dec 2024). This isn’t just visibility; it’s a substantial foundation for future growth.

CEO Dr. Frank Mathias attributes this to the “fully in place” multi-vector, multi-site model driving operational and commercial progress, translating into growing client trust. The focus on “operational excellence and cost discipline” shines through in the reiterated profitability target.

The Engine Room: Late-Stage Demand & Strategic Execution

So, what’s fuelling this acceleration?

• Late-Stage Lentiviral Surge: Demand is particularly strong for late-stage and commercial lentiviral programmes. This isn’t just lab work; it’s the critical path to getting therapies to patients (and generating significant, sustained revenue for OXB).
• Multi-Site Synergy Kicking In: The strategic integration of UK, US, and French sites is demonstrably paying off. Completing the acquisition of the remaining 10% of OXB US LLC solidifies control and further streamlines the global network. This geographic spread isn’t just convenient; it’s a major risk mitigator and client enabler.
• AAV Momentum Building: While lentivirus grabs headlines, AAV activity is also growing steadily, meeting expectations and broadening OXB’s service appeal.

Scaling Smartly for the Future

OXB isn’t resting on its laurels. To handle this burgeoning demand and expected future growth, they’re proactively managing capacity: